Clinical Trials | September 03, 2024
Tolebrutinib meets primary endpoint in HERCULES phase 3 study
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Stressed was on the need to promote organ donation from the deceased persons to meet the huge need for organ donation in the country
The study highlighted substantial improvements in key clinical parameters among RA patients who underwent AWS intervention
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Against targeted investment of Rs. 3,938 crore, investments worth Rs. 4,024 crores have been made under scheme
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Subscribe To Our Newsletter & Stay Updated
